Immune response to viral infection is an important determinant of liver injury in chronic hepatitis C (CHC). Experimental and clinical data suggest a protective role of interleukin-10 (IL-10) in hepatic fibrogenesis. The significance of two SNPs of the interleukin-10 receptor 1 (IL-10R1), S138G (SNP3) and G330R (SNP4) was investigated on (i) susceptibility to CHC, (ii) progression of hepatic fibrosis and (iii) response to interferon/ribavirin therapy. DNA and liver biopsies were obtained from 212 patients with HCV (hepatitis C virus)-genotype-1 infection. The allele frequencies were 0.17 for SNP3 and 0.33 for SNP4, both of which were indifferent from healthy controls (0.17 and 0.32, respectively). Stage 1 liver fibrosis was found in 22 cases (10.4%), stage 2 in 108 (50.9%), stage 3 in 27 (12.8%), and stage 4 (cirrhosis) in 55 (25.9%). An association was found between the SNP4 allele and the presence of cirrhosis (P ¼ 0.01). Homozygous SNP4 individual variants segregated within the cirrhosis group (P ¼ 0.03). We found neither an association with SNP3 nor with the necroinflammatory disease activity (as measured by ALT levels) nor with the response to antiviral therapy. Our work implies that IL-10R1 SNP4 is a recessively inherited risk factor for hepatic cirrhosis in HCV genotype-1 infection.
Introduction
The natural history of chronic hepatitis C (CHC) is variable. Chronic hepatitis develops in 33-84% of patients with acute hepatitis C. [1] [2] [3] [4] Once, chronicity has established, about one-third of patients develop liver cirrhosis within 15-25 years 5, 6 with an annual risk of hepatocellular carcinoma in 1-4% in cirrhotic livers. [7] [8] [9] Several factors such as alcohol abuse, coinfection with HBV or HIV, gender or age at infection determine the highly variable course of liver disease in hepatitis C virus (HCV) infection. 5, [10] [11] [12] Besides, the hepatocellular injury in patients with CHC results from the host's immunemediated responses to viral infection. In this respect, the host's immunogenetic make-up plays an important role in determining the natural history of CHC. Some evidence for the involvement of host genetic factors in the outcome of HCV infection exists. [13] [14] [15] Antiviral therapy of CHC with pegylated interferon alfa-2a or -2b and ribavirin yields HCV eradication rates from 54 to 56% 16, 17 and sustained response might diminish fibrosis. 18 However, antiviral therapy carries substantial morbidity at high costs. Therefore, it is of particular interest to select individuals at risk for disease progression who would benefit most from antiviral therapy.
Interleukin 10 (IL-10) is a cytokine that exerts a variety of immunoregulatory activities, which affect both innate and cell-mediated immunity. 19 With respect to chronic liver diseases it is of special interest that a decrease of IL-10 mRNA concentrations was found in the liver of patients chronically infected with HCV. 20 IL-10-deficient mice are susceptible to hepatic inflammation induced by chemical compounds. 21 IL-10 has the ability to modulate extracellular matrix remodeling by reducing collagen type 1 and enhancing collagenase and stromelysin gene expression. 22 Activation of hepatic stellate cells was shown to cause autocrine expression of IL-10 resulting in a negative autoregulatory effect on collagen production. 23 In addition, clinical studies demonstrated that IL-10 reduces necroinflammatory activity and progression of fibrosis in patients with CHC 24, 25 and downregulates collagen synthesis in skin fibroblasts. 26 IL-10 mediates its biological effects by binding to the IL-10 receptor, which is a hetero-tetramer consisting of two of each receptor chains (IL-10R1 (interleukin-10 receptor 1) and IL-10R2), which belong to class II cytokine receptor family.
19,27-29 The IL-10R1 chain plays a dominant role in mediating high-affinity ligandbinding and signal transduction, whereas the IL-10R2 subunit is thought to be required for signaling.
30,31
Interaction of IL-10 with the IL-10R complex stabilizes dimerization of both IL-10R subunits, activates phosphorylation of the receptor-associated Janus tyrosine kinases, Jak1 and Tyk2 32, 33 and induces mainly STAT3-mediated signal transduction. [34] [35] [36] Our group recently identified two novel SNP of the IL-10R1, 37 one of which (G330R, SNP4) affects IL-10-mediated inhibition of TNFa production in human monocytes. 37 The other SNP, S138G (SNP3), is genetically linked to SNP4. Modeling of the extra cellular receptor domain of the IL-10/ IL-10R1 SNP3 complex revealed that this serine to glycine exchange may produce certain conformational rearrangements of this receptor domain.
The aim of the present study was to investigate the effect of these coding SNPs on (i) susceptibility to chronic HCV-1 infection; (ii) progression of hepatic fibrosis; and (iii) response to interferon/ribavirin therapy in CHC.
Results
In total, 212 patients with CHC (137 female, mean age: 44.7711.2, years7s.d., median ALT: 2.36 (1.1-10.1) ( Â ULN, (range)) were prospectively enrolled in this study. To avoid additional confounding variables (eg age, duration of disease, mode of transmission), only patients infected with HCV genotype-1 were included. The allele frequencies (0.17 for S138G (SNP3), 0.33 for G330R (SNP4)) were indifferent from 887 healthy controls (0.17 for SNP3, P ¼ 0.83, 0.32 for SNP4; P ¼ 0.61). The genotype distribution of SNP3 was GG 7 (3.3%), AG 58 (27.4%), and AA 147 patients (69.3%) and was indifferent from controls (GG: 24 (2.7%), AG: 249 (28.1%), AA: 614 (69.2%); P ¼ 0.88). The genotype distribution of SNP4 was AA 27 (12.7%), AG 85 (40.1%), GG 100 patients (47.2%). The corresponding data in control subjects were AA 78 (8.8%), AG 403 (45.4%), GG 406 (45.8%); P ¼ 0.14.
All patients had undergone liver biopsy prior to initiation of antiviral therapy. Stage 1 liver fibrosis was found in 22 (10.4%), stage 2 in 108 (50.9%), stage 3 in 27 (12.8%) and stage 4 in 55 (25.9%), respectively. The stage of fibrosis increased with age and disease duration (Table 1 ). An association was detected between the SNP4 allele and the stage of fibrosis (P ¼ 0.01 for allele frequency, and P ¼ 0.03 for genotype, Table 2 ). Out of 27 individuals who were homozygous for SNP4, 12 (44%) presented with stage 4 fibrosis (cirrhosis). The SNP4 genotype in this group differed from HardyWeinberg (P ¼ 0.026, OR: 2.68, CI: (1.09-6.52)) with a shift towards homozygous individuals. Homozygous individuals, however, were of similar age (51 (46-60) vs 52 (38-70)) and duration of disease (28 (22-33) vs 30 (24-40); years, median (range)). No association was seen for SNP3 (Table 2 ).
To test for a possible effect of IL-10R1 variants on the inflammatory response to hepatitis C infection, we compared the baseline necroinflammatory activity reflected in alaninaminotransferase (ALT) levels between the IL-10R1 genotypes. Both IL-10R1 variants had no effect on ALT levels ( Figure 1 ). This was unexpected since ALT levels are typically higher in advanced fibrosis, which was more prevalent in homozygous IL-10R1 SNP4 carriers. We further compared ALT levels according to the stage of fibrosis. ALT levels were indeed higher in patients with advanced fibrosis (stage 3 and 4) compared to early fibrosis (stage 1 and 2) (2.87 (1.1-10.1) vs 2.2 (1.1-5.9); Po0.001; median ALT (IUxULN) (range)). Next, this comparison was stratified for the various IL-10R1 genotypes ( Table 3) . The difference in ALT levels remained present in IL-10R1 wild-type individuals, but was absent in heterozygous or homozygous individuals. This finding supports the hypothesis that the profibrotic activity of IL-10R1 SNP4 is independent of the necroinflammatory activity in CHC.
In total, 81 patients (40.9%) were sustained virological responders, and 117 (59.1.%) were nonresponders or relapser to interferon/ribavirin combination therapy. The presence of cirrhosis was associated with viral persistence: 13 patients (25.5%) with cirrhosis achieved sustained virological response compared to 68 (46.3%) without cirrhosis (P ¼ 0.009). There was no association between the IL-10R1 variants and the response to antiviral therapy (SNP3 genotype: P ¼ 0.73; SNP4 genotype: P ¼ 0.87).
Discussion
The impact of host genetic factors on disease progression in CHC has been suggested with respect to several genetic variations. 14 In this work we demonstrate that the IL-10R1 variant G330R (SNP4) is associated with the presence of cirrhosis. Since this was found to be most prevalent in homozygous individuals, our work implies that IL-10R1 SNP4 is a recessively inherited risk factor for hepatic fibrosis in HCV genotype-1 infection.
We have previously demonstrated that the IL-10R1 SNP4 is associated with a diminished response to IL-10 in cultures from peripheral blood monocytes. 37 Specifically, monocytes from homozygous mutant individuals were not capable to completely downregulate LPSinduced TNF-alpha production upon high doses of IL-10. Also, the ID50 (the IL-10 concentration that caused a 50% reduction of LPS-induced TNF-alpha production) was significantly higher in monocytes from homozygous mutant individuals. Though the exact mechanism behind this observation is still not clear, the IL-10R1 SNP4 is regarded as a recessive loss-of-function allele. By transferring these findings into the setting of CHC, homozygous SNP4 individuals would be expected to 38 and to reduce the necroinflammatory activity and progression of fibrosis in patients with CHC in vivo, 39, 40 our findings are compatible with what has been hypothesized. The protective role of IL-10 signaling in CHC is probably not HCV-genotype specific and our results may be transferred to individuals with other HCV genotypes, with the exception of HCV genotype-3a that is endemic in i.v. drug abusers, a cohort with significant co-morbidity (alcohol abuse, HBV, HIV). To exclude such bias we limited this study to HCV genotype 1 and controlled for age and disease duration. In addition, liver biopsies were evaluated by a single pathologist thereby avoiding any interobserver variation.
In the same respect it is tempting to speculate that the progression of other forms of chronic liver injury such as alcohol-induced liver fibrosis, chronic hepatitis B, or hemochromatosis may be altered by the presence of IL-10R1 SNP4. From a worldwide genotype analysis we know that SNP4 is most prevalent in Caucasians, Semites (including Arabs) and to a lesser degree in sub-Saharan Africans, but virtually absent in Asian and the Native American populations. 41 Therefore, the IL-10R1 SNP4-associated risk of progressive liver disease varies between populations and can be neglected in Asians. On the other hand, the relevance of our finding for high prevalence areas (such as Russia with 45% SNP4) should be considered and tested in independent studies.
A correlation between cytokine gene polymorphisms and outcome of HCV infection has been demonstrated. [12] [13] [14] Several groups have reported an association between IL-10 promotor polymorphism and outcome of HCV infection with diverse results. [42] [43] [44] [45] In our HCV genotype-1 patients we could not find an association between the presence of IL10-R1 variants and response to antiviral therapy. In addition there was no difference in allele frequencies comparing control individuals and patients with CHC indicating no role for the polymorphism in disease susceptibility.
Our data emphasize an involvement of IL-10R1 signaling in the progression of liver fibrosis in patients with CHC genotype-1 that is independent of the necroinflammatory activity as measured by ALT levels. It is remarkable that in patients carrying IL-10R1 variants, the presence of advanced fibrosis did not result in higher ALT levels as it is observed in patients carrying the wild-type gene. Since the number of individuals in the variant group is smaller than in the wild-type group, this finding could be due to lack of statistical power. At the moment, however, we may interpret this finding as evidence for an inflammation-independent profibrotic effect.
In summary, our data indicate that inherited variations in IL-10R1 may contribute to the development of liver cirrhosis in CHC. This finding adds evidence to the hypothesis that the host's immunogenetic background changes the progression of liver disease in CHC.
Patients and methods

Patients
Liver biopsies had been obtained from 212 consecutive interferon-naïve patients with CHC genotype 1 (m ¼ 137, f ¼ 75, mean age: 44.7711.2) as part of evaluation for antiviral therapy. These patients had participated in prospective clinical trials on treatment of CHC (comparing various treatment schedules of standard IFN/ ribavirin therapy and pegylated IFN-alfa2a/ribavirin therapy) 17, [46] [47] [48] and had completed both the study treatment and a 6 months post-treatment observation period. All patients had increased serum aminotransferase levels for at least 6 months prior to interferon therapy, and were serum anti-HCV antibodies and HCV-RNA positive. Exclusion criteria were alcohol abuse (weekly ethanol consumption of more than 50 g for males 
Genotyping of IL-10R1 variants
Two allele-specific polymerase chain reaction (PCRs) were used for detection of IL-10R1 SNP3 and SNP4 in genomic DNA as described. 37 The PCR products of the SNP3 reaction are 464-bp (control PQ-138), 337-bp (wildtype AQ-138) and 183-bp (variant PB-138). The PCR products of the SNP4 reaction are at 515-bp (control PQ-330), 318-bp (wild-type AQ-330) and 248-bp (variant PB-330). In total, 40 cycles of amplification were performed with AmpliTaq Gold (Applied Biosystems). Figure 1 ALT levels according to the IL-10R1 S138G (a) and IL-10R1 G330R genotype (b). To identify an influence of IL-10R1 S138G (SNP3) or IL-10R1 G330R (SNP4) on the degree of hepatic inflammation, we compared alaninaminotransferase (ALT, x upper limit of normal, xULN) levels that were measured before antiviral therapy between the different IL-10R1 genotypes. SNP3 ((a) G allele; P ¼ 0.984 by Kruskal-Wallis) and SNP4 ((b) A allele; P ¼ 0.994 by Kruskal-Wallis) were not associated with a higher ALT levels, indicating that the effect of SNP4 on hepatic fibrosis is independent of the degree of hepatic inflammation. Bars represent the median values and boxes, the 25 and 75% quartiles. IL-10R1 variants and chronic hepatitis C H Hofer et al
Statistical analysis
